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ABSTRACT 
    
     Acute lymphoblastic leukemia (ALL) is one of the most common cancers among children. Although 
there have been tremendous treatments, none of them have led to a precise cure. The use of herbal 
medicines which are safe and non-toxic have been demonstrated in this study. Curcumin is a polyphenol, 
hydrophobic product that is derived from turmeric plant. Curcumin has anti-toxic, anti-bacterial, anti-
inflammatory, anti-cancer and anti-apoptosis properties. In recent years, extensive researches have been 
performed over the use of curcumin on cancers. In this study, CCRF-CEM cell line has been treated by 
curcumin. Rate of cytotoxicity of curcumin and the viability of the cells after treatment were evaluated by 
MTT assay and flow cytometry analysis. When different concentrations of curcumin were used upon the 
CCRF-CEM cell line at different times, it was found that curcumin effect depended on dose and time 
pattern. The results revealed that curcumin could induce apoptosis in CCRF-CEM cell line of acute 
lymphoblastic leukemia. 
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INTRODUCTION      
       Cancer develops due to genetic mutations in 
oncogenes and tumor suppressor genes, and has 
been regarded as one of the major causes of death 
in the world.  [1, 2].  One of the cancers prevalent 
in people aged under twenty is acute 
lymphoblastic leukemia caused by malignancy of 
T or B cells [3, 4]. Until today various treatments 
have been carried out on cancers, and yet not 
often have they lead to the prevention of tumor 
recurrence. Natural compounds with safety and 
lack of toxicity have resulted in renewed hope in 
the treatment of cancer [5]. Curcuma Longa is a 
perennial plant and a member of the ginger 
family which is a curcuminoid most abundant in 
Turmeric [6]. For the first time, curcumin was 
extracted by Vogel in 1815 [7, 8, and 9]. The 
molecular formula of curcumin is C21H20O6 [9]. 
Since 1987, the National Cancer Institute has 
conducted experiments on over 1000 different 
materials to achieve the anticancer reaction. 
Curcumin is one of the materials recognized to be 
effective for cancer research. Due to the 
application of curcumin in the diet for centuries, 
it can be characterized as completely safe for 
pharmaceutical use [6, 10]. Studies on curcumin 
showed that it has anti-toxic, anti-bacterial, anti-
viral, anti-inflammatory, anti-malarial and 
antioxidant properties [6, 11]. According to 
clinical findings first reported by Kuttan et al, 
curcumin has anti-cancer activity as well as 
induced apoptosis. According to the clinical 
studies, the usage of curcumin up to 12 g/ day is 
easily tolerated [7, 10]. Curcumin with its variety 
of functionsand potent anticancer activity can 
prevent progression, metastasis and angiogenesis 
in tumors. Unlike the other drugs, curcumin has a 
variety of targets such as proteins, transcription 
factors, growth factors, receptors, cytokines, 
enzymes and etc. [12]. As curcumin can react 
with 30 different proteins, it is able to induce 
apoptosis due to multiple signaling pathways [13, 
11]. Curcumin can inhibit both NF-κB and AP-1 
(activator protein 1) which are transcription 
factors and increase the expression of genes 
involved in inflammation, proliferation and cell 
growth in many cancers. [6]. Curcumin can also 
inhibit the activity of a tyrosine kinase receptor 
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named HER2/neu and other epidermal growth 
factor receptors and suppresses breast cancer cells 
[14]. (human epidermal growth factor receptor2, 
c-erbB-2 and human EGF receptor 2 are the other 
names of HER2/neu). According to some studies,  
curcumin induces apoptosis of breast cancer cells 
as well as leukemia [15, 16]. In this experimental 
study, curcumin has been used to treat the CCRF-
CEM cell lines of acute lymphoblastic leukemia, 
wherethe apoptotic activity of curcumin was 
investigated. 
 
MATERIALS AND METHODS 
   The required purchase was done as follows: 
Curcumin from Riedel-de Haen. Dimethyl 
sulfoxide [DMSO]; MTT from Sigma America; 
CCRF-CEM cell line of acute lymphoblastic 
leukemia from Pasteur Institute of Iran; RPMI 
1640 medium and pen / Strep Caisson America, 
and  FBS from Gibco America. 
Cell culture 
     CCRF-CEM cell lines were cultured in RPMI-
1640 containing 10 % FBS, 1% pen/strep under a 
humid condition [37 °C, 5 % CO2, 95 % air]. 
MTT assay 
     MTT assay is one of the in vitro widely used 
ways to evaluate the relative number of the viable 
cells after treatment with drugs. The 
mitochondrial succinate dehydrogenase enzymes 
in living cells can revive the yellow MTT to a 
purple color which can be measured by ELISA 
reader at 570nm. . 1×104 CCRF-CEM cells were 
plated in  96-well plates.After 24 hours, the cells 
were treated using 6.25, 12.5, 25 and 50 μg/ml 
concentrations of curcumin in RPMI medium 
containing 1% Pen Strep separately. Each 
concentration was considered in 8 wells. The 
plates were incubated at 37°C for 24, 48 and 72 
hours. 10μL of MTT (5mg/mL) was added to 
each well and the plates were incubated at 37°C.  
After 2 to 4 hours, 100 μl DMSO was added to  
each well and mixed till the pellets  were     dis 











Viability % = 100 - Cytotoxicity % 
Flow cytometry analysis 
     To evaluate the rate of cytotoxicity of 
curcumin and the viability of the cells after 
treatment, flow cytometry analysis was 
performed. For this purpose the annexin 
V/propidium iodide assay was performed 
according to the manufacturer’s recommendation. 
Briefly, CCRF-CEM cells were plated into a 12-
well plates and incubated for 24, 48 and 72 hours 
with 50 μg/ml concentration of curcumin. The 
cells were collected, centrifuged and washed with 
calcium buffer.  Annexin V [10 μl] was added to 
the cells and were incubated on ice for 20 minutes 
in the darkness. Then the cells were centrifuged 
and washed with calcium buffer again. PI [10 μl] 
was added to the cells and incubated on ice for 10 
minutes. At the end, calcium buffer [300 μl] was 




Vital capacity test after treatment with curcumin 
by MTT assay 
     The results of curcumin effects on CCRF-
CEM cell lines were analyzed by MTT assay in 
different times and concentrations, and are shown 
in Figure1. IC50 concentrations of curcumin at 24, 
48 and 72 hours, were about 50, 25 and less than 
6.25 μg/ml respectively.  
Pro-apoptotic capacity test after treatment with 
curcumin by flow cytometry assay 
     The results of the apoptotic effects of 50 μg/ml 
curcumin on CCRF-CEM cell line after 24, 48 
and 72 hours are shown in Figure 2. According to 
the obtained results, the percentage of treated 
living cells with curcumin is significantly 
different with control cells.  
  
 




Figure 1.  Viability effects of curcumin on CCRF-CEM cell 
line 
 
Figure 2.  Apoptotic effects of curcumin on CCRF-CEM 
cell line by flow cytometry 
 
DISCUSSION 
     Cancer has been regarded as a significant 
1
health threat and the second cause of mortality in 
developed countries [17]. BCR-ABL1  occurs in 
                                                          
1
 a reciprocal translocation, t (9; 22) (breakpoint cluster 
region gene locus-Abelson leukemia, abl gene locus) 
 
adults with acute lymphoblastic leukemia more 
than children. Unlike the chronic myeloid 
leukemia, the disease does not improve with 
chemotherapy and bone marrow transplantation 
[3]. Despite the tremendous progress in 
treatmentof cancer, the problem of multidrug 
resistance. remains a real problem in blood, 
breast, and ovaries cancers and etc. [17]. First, 
Natural products have been used to cure patients 






Figure 3. Apoptotic effects of curcumin (50 μg/ml ) on 
CCRF-CEM cell line at 48h by flow cytometry  
 
Curcumin as a natural active polyphenol has anti-
cancer effects and has been used in the treatment 
of various diseases including diarrhea, jaundice, 
ulcers, etc [2]. Curcumin through its different 
signaling pathways has different molecular  
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targets and regulates cell proliferation and 
apoptosis [1]. The caspases, a family of cysteine-
aspartate proteases, plays an important role in 
necrosis, apoptosis and inflammation. According 
to the numerous reports, curcumin promotes  
apoptosis by inducing Caspases [18]. It is 
demonstrated that curcumin can be effective on 
stem cell cancer in multiple pathways by 
Klonisch et al. and Kakarala et al. in 2008 and 
2010 [19, 20]. Curcumin inhibits the main 
characteristics of cancers that increase expression 
of the biomarkers, such as CD133, CD44, CD166 
and ALDH1. This can change the morphology of 
stem cells cancer [19, 20]. Anad et al and 
Shehzad et al in 2008 and 2010 found that 
curcumin is effective on several genes linked to 
breast cancer, such as NF-κB, AP-1, COX-1, 
VEGF, cyclin E, factor fibroblast growth (FGF), 
IL-6, IL-11, MMP-9 and MMP-13 and also on 
the up-regulation on P21 and P27 [21, 22]. In 
2011, while doing researches on patients with 
colorectal cancer, it was demonstrated that 
curcumin increases the amount of P53, which 
conduces to improve patients [23]. Aggarwal et 
al. and Dorai et al. in 2008 and 2001 while 
working on the patients with prostate cancer 
demonstrated that treatment of those patients with 
curcumin inhibited angiogenesis and proliferation 
[24, 25].  
Watson et al (2001) during treatment of the 
patients with ovarian cancer by curcumin found 
that Bcl2 expression and Survivin, which are anti-
apoptotic proteins were decreased; it  also created 
a down regulation of Akt signaling and an 
activation of p38-MAPK [26]. 
 
CONCLUSION 
     We used curcumin on CCRF-CEM cell line in 
acute lymphoblastic leukemia to find out growth 
inhibition and induction of apoptosis. The results 
of this study showed that curcumin can inhibit 
cell growth and can also induce apoptosis in 
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